Car-t immunotherapy for cd19-negative leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of CAR-T therapy (a treatment that trains your immune cells to attack cancer) for people with certain types of B-cell leukemia that are CD19 negative or have relapsed after CD19 treatment. It may help if your cancer has other markers like CD22 or CD123.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 6 months.
- Your cancer cells must be CD19 negative (meaning they don't have the CD19 marker) or have come back after a previous CD19 treatment.
- Your cancer cells must have at least one of these markers: CD22, CD123, CD38, CD10, CD20, or TSLPR.
- You must be in fairly good health (able to be up and about) and expected to live at least another month.
- Your hemoglobin (a blood protein that carries oxygen) must be above 80 g/L.
- You must not have major active infections (like HIV, hepatitis B or C) or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a special cell therapy that targets two markers on cancer cells to treat certain blood cancers. It may help people whose cancer has not gotten better with other treatments.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins (CD19 and CD70) on your cancer cells. It is for patients with B-cell cancers that didn't respond to previous treatments.
This trial tests a new type of immune cell therapy (4SCAR19U T cells) designed to attack B-cell cancers. It may be an option if your cancer has the CD19 protein and you haven't had a prior CAR-T treatment that failed.
This trial tests a personalized cell therapy that uses your own immune cells, modified to better find and attack lymphoma cells. It may help when standard treatments have not worked.
This trial tests a new type of immune cell therapy called CAR-T cells that are designed to find and destroy cancer cells with the CD19 or CD22 markers. The goal is to see if this experimental treatment can help people with B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma when other treatments haven't worked.
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
Hear when a new Leukemia, B-cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.